Schmaltz Cornelius, Alpdogan Onder, Kappel Barry J, Muriglan Stephanie J, Rotolo Jimmy A, Ongchin Jennifer, Willis Lucy M, Greenberg Andrew S, Eng Jeffrey M, Crawford James M, Murphy George F, Yagita Hideo, Walczak Henning, Peschon Jacques J, van den Brink Marcel R M
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Nat Med. 2002 Dec;8(12):1433-7. doi: 10.1038/nm1202-797. Epub 2002 Nov 11.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that exhibits specific tumoricidal activity against a variety of tumors. It is expressed on different cells of the immune system and plays a role in natural killer cell-mediated tumor surveillance. In allogeneic hematopoietic-cell transplantation, the reactivity of the donor T cell against malignant cells is essential for the graft-versus-tumor (GVT) effect. Cytolytic activity of T cells is primarily mediated through the Fas-Fas ligand and perforin-granzyme pathways. However, T cells deficient for both Fas ligand and perforin can still exert GVT activity in vivo in mouse models. To uncover a potential role for TRAIL in donor T cell-mediated GVT activity, we compared donor T cells from TRAIL-deficient and wild-type mice in clinically relevant mouse bone-marrow transplantation models. We found that alloreactive T cells can express TRAIL, but the absence of TRAIL had no effect on their proliferative and cytokine response to alloantigens. TRAIL-deficient T cells showed significantly lower GVT activity than did TRAIL-expressing T cells, but no important differences in graft-versus-host disease, a major complication of allogeneic hematopoietic cell transplantation, were observed. These data suggest that strategies to enhance TRAIL-mediated GVT activity could decrease relapse rates of malignancies after hematopoietic cell transplantation without exacerbation of graft-versus-host disease.
肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)是TNF超家族的成员,对多种肿瘤具有特异性杀瘤活性。它在免疫系统的不同细胞上表达,并在自然杀伤细胞介导的肿瘤监视中发挥作用。在异基因造血细胞移植中,供体T细胞对恶性细胞的反应性对于移植物抗肿瘤(GVT)效应至关重要。T细胞的细胞溶解活性主要通过Fas-Fas配体和穿孔素-颗粒酶途径介导。然而,在小鼠模型中,Fas配体和穿孔素均缺陷的T细胞在体内仍可发挥GVT活性。为了揭示TRAIL在供体T细胞介导的GVT活性中的潜在作用,我们在临床相关的小鼠骨髓移植模型中比较了来自TRAIL缺陷小鼠和野生型小鼠的供体T细胞。我们发现同种反应性T细胞可以表达TRAIL,但TRAIL的缺失对其对同种抗原的增殖和细胞因子反应没有影响。与表达TRAIL的T细胞相比,TRAIL缺陷的T细胞显示出明显更低的GVT活性,但在移植物抗宿主病(异基因造血细胞移植的主要并发症)方面未观察到重要差异。这些数据表明,增强TRAIL介导的GVT活性的策略可以降低造血细胞移植后恶性肿瘤的复发率,而不会加重移植物抗宿主病。